Bionet

Bionet EBIT Margin

The EBIT Margin (Operating Margin) of Bionet (1784.TWO) as of Nov 2, 2026 is -0.98 %. In the previous year, EBIT Margin (Operating Margin) was 5.16 % — a change of -118.99% (lower).

EBIT Margin

-0.98 %

YoY

-118.99%

Last updated:

EBIT Margin (Operating Margin) of Bionet is 2025 -0.98 % . EBIT Margin (Operating Margin) of Bionet was 2024 5.16 % . It decreases by -118.99% lower compared to the previous year.

Bionet's operating (EBIT) margin stands at -1.0%, down from 4.5% several years earlier.

The Bionet EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
4.43 TWD
Jan 1, 2019
1.14 TWD
Jan 1, 2020
0.94 TWD
Jan 1, 2021
4.55 TWD
Jan 1, 2022
7.55 TWD
Jan 1, 2023
9.68 TWD
Jan 1, 2024
5.16 TWD
Jan 1, 2025
-0.98 TWD
The Bionet EBIT Margin history
YEAREBIT MarginYoY
-0.98 %-118.99%
5.16 %-46.73%
9.68 %+28.13%
7.55 %+66.07%
4.55 %+384.90%
0.94 %-17.63%
1.14 %-74.31%
4.43 %-1,184.86%
-0.41 %-88.57%
-3.57 %+1,249.81%
-0.26 %-73.54%
-1.00 %-15,928.96%
0.01 %-92.65%
0.09 %+132.33%
0.04 %-160.51%
-0.06 %-159.10%
0.10 %-36.23%
0.16 %+9.39%
0.15 %+378.31%
0.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bionet Stock analysis

What does Bionet do? Bionet Corp. generates revenue through cell therapy, regenerative medicine, and medical big data services. Its main products include umbilical cord blood stem cells, mesenchymal stem cells, and adult peripheral blood stem cells, which are sold to domestic healthcare providers. The company also offers precision medical applications, prenatal testing, and genetic testing services to domestic clients. The firm primarily serves the domestic market within Taipei City, Taipei, focusing on medical and healthcare segments. Bionet Corp. targets healthcare institutions and medical facilities in Taiwan as its primary customers. The company's product portfolio includes stem cell therapies and genetic testing services, which are distributed through its domestic operations. Revenue streams are derived from both the sale of biological products and the provision of specialized medical services within the local market. The business model relies on domestic sales of stem cell-based therapies and genetic testing services. Products such as umbilical cord blood stem cells and mesenchymal stem cells are key revenue drivers, alongside precision medical applications and prenatal testing. All operations are conducted within Taiwan, with no mention of international markets or external partnerships. Bionet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bionet stock

EBIT Margin (Operating Margin) of Bionet is -0.98 % in 2025.

EBIT Margin (Operating Margin) of Bionet changed from 5.16 % to -0.98 %, representing a -118.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Bionet since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Bionet with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Bionet

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Bionet